1. Scrip
  2. >>Focus On Asia

Novartis/BeiGene Opt For PD-1/TIGIT Combo For NSCLC In US

Defocus On 2L Monotherapy

 
• By Dexter Jie Yan

The two companies have ceased to seek US approval for tislelizumab as a monotherapy for second-line non-small cell lung cancer and are instead seeming to pin their hopes on a combination with BeiGene’s anti-TIGIT antibody ociperlimab in the first-line setting.

Novartis/BeiGene to shift gears
Novartis/BeiGene shift US clinical strategy for non-small cell lung cancer • Source: Shutterstock

Novartis AG and Chinese partner BeiGene, Ltd. are opting to focus on a combination approach for their PD-1 checkpoint inhibitor tislelizumab in non-small cell lung cancer (NSCLC) in the US, after scrapping a plan to file a biologics license application with the US Food and Drug Administration.

On 19 July, Novartis disclosed in its second-quarter report that it had decided not to move forward with the original plan to submit a BLA in the second half of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.